Dr Reddy’s Joins Remdesivir Licensees
Firm Adds To Others That Have Struck Deals With Gilead
Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.
You may also be interested in...
Gilead Scales Up Remdesivir Production To Meet Indian Demand
To tackle the increase in demand for remdesivir in India amidst the second wave of COVID-19, Gilead Sciences is helping local licensees to scale up production of the product, including by providing API supplies. The company is also donating at least 450,000 vials of the Veklury brand “to help address the immediate needs of Indian patients.”
Asia Deal Watch: Lupin Signs Up Three EU Marketing Partners For NaMuscla
Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.
Searle Licenses Beximco’s Remdesivir For Pakistan
Pakistan’s Searle says it has struck a licensing and marketing deal with Bangladesh’s Beximco to market its generic remdesivir in Pakistan as the country grapples with the coronavirus pandemic.